Travere Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +96.0%
EBITDA: +122.9%
EBIT: +74.8%
EPS: +82.6%
Free cash flow: +99.1%
Operating cash flow: +124.7%

Forward estimates

Revenue: +54.5%
EBITDA: —
EPS: +281.2%

Three-year CAGR

Revenue: +64.9%
EBITDA: +108.4%
EBIT: +80.6%
Net income: +92.1%
EPS: +86.3%
Free cash flow: +94.0%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.